Ms Mary Day:

In fairness, these biosimilars are just coming onto the market. Much research must be done before they come onto the market to ensure the effectiveness of these products. Once the pharmacies and laboratories in the group hospitals become aware of them we speak to our clinicians about ensuring we get the best value for the spend. There is an accountability issue, which is something Dr. O'Reilly has already has mentioned, which is absolutely right. We are accountable for the services we deliver. Of course we look at areas where we can bring in efficiencies, such as laboratories, radiology and drugs spend.